Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem® in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at risk of developing ACLF has been selected by the European Association for the Study of the Liver (EASL) for an oral presentation, by the principal investigator (Prof. F. Nevens, KULeuven, BE) during the plenary general session at The International Liver Congress™ (ILC) 2019 being held April 10-14, 2019, in Vienna, Austria. Discover the press release here.
Masthercell announces today that it has signed a lease agreement for a 5.700 m² facility located in Gosselies. The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially-approved cell and gene therapy products. The commercial facility is expected to be operational in early 2021. Discover the press release here.